Inferra AIResearch Tools

Inferra AI / Company / CHE

Chemed Corp

CHE · Health Care

Last earnings Oct 27, 2026

Key results

Revenuequarter

3.1%

Revenue increased 3.1% to $624.9 million &#xB7

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Adjusted EPSquarter

$5.27

Adjusted Diluted EPS of $5.27, a decrease of 6.6% &#xFEFF

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Net Patient revenuequarter

$407.7 million

Net Patient Revenue of $407.7 million, an increase of 4.2% &#xB7

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Revenue of $217.2 million, an increase of 1.1% &#xB7

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

revenue was $407.7 million in the third quarter of 2025, which is an increase of 4.2% when compared to the prior-year period.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

This revenuequarter

2.5%

This revenue increase is comprised primarily of a 2.5% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 4.1%.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Average revenuequarter

$205.08

 Average revenue per patient per day in the third quarter of 2025 was $205.08 which is 298-basis points above the prior-year period.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

 Roto-Rooter  Roto-Rooter generated quarterly revenue of $217.2 million in the third quarter of 2025, an increase of 1.1%, when compared to the prior-year quarter.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

AI analysis

Q3 2025 · reported Oct 28, 2025

Based on: Earnings release + parent 8-K + 10-K — transcript not held

Adjusted EPS · Q3 2025
$5.27
EX-99 · Oct 28, 2025
Net Patient revenue · Q3 2025
$407.7M
EX-99 · Oct 28, 2025
Average revenue · Q3 2025
$205.08
EX-99 · Oct 28, 2025

Headline figures

MetricQ3 2025Prior qtrYear ago
Revenue3.1%——
Adjusted EPS$5.27——
Net Patient revenue$407.7 million——
This revenue2.5%——
Average revenue$205.08——

EX-99 · Oct 28, 2025

Guidance · company-stated

Direction: Reiterated

Company outlook

“ Reiterate Guidance for 2025  Management reiterates its previously issued guidance of $22.00 to $22.30 per share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

 Chemed Consolidated  As of September 30, 2025, Chemed had total cash and cash equivalents of $129.8 million and no current or long-term debt.

This Credit Agreement consisted of a $100 million amortizable term loan and a $450 million revolving credit facility.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Witzeman (513) 762- 6714  Chemed Reports Third-Quarter 2025 Results &#xFEFF

Based on: Earnings release + parent 8-K + 10-K — transcript not held

Guidance & outlook

Direction: Reiterated

Company outlook: “ Reiterate Guidance for 2025  Management reiterates its previously issued guidance of $22.00 to $22.30 per share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items.”

Company outlook — Reiterated (“Reiterate”)
“ Reiterate Guidance for 2025  Management reiterates its previously issued guidance of $22.00 to $22.30 per share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items.”

Classified from the release's primary full-year outlook statement.

Capital allocation

 Chemed Consolidated  As of September 30, 2025, Chemed had total cash and cash equivalents of $129.8 million and no current or long-term debt.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

This Credit Agreement consisted of a $100 million amortizable term loan and a $450 million revolving credit facility.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

There is approximately $404.5 million undrawn borrowing capacity under the Credit Agreement after excluding $45.5 million for Letters of Credit.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

 During the quarter, the Company repurchased 407,500 shares of Chemed stock for $180.8 million which equates to a cost per share of $443.62.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

As of September 30, 2025, there was approximately $301.8 million of remaining share repurchase authorization under its plan.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company’s operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Strategy & priorities

This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Chemed s corporate office management participates in and is ultimately responsible for long term strategic planning, significant capital allocation decisions, investment activities, financial reporting, tax, legal and the selection of the key executives of each of the operating businesses.

SEC original ↗Chemed Corp — 10-K Annual report10-KFeb 27, 2026

Additionally, if any state or federal agency places a moratorium on new hospices or hospice expansion in any geography, it could adversely affect VITAS growth potential.

SEC original ↗Chemed Corp — 10-K Annual report10-KFeb 27, 2026

A few states have laws that restrict the development and expansion of for-profit hospice programs.

SEC original ↗Chemed Corp — 10-K Annual report10-KFeb 27, 2026

There currently are numerous legislative and regulatory initiatives at both the state and federal levels that address patient privacy concerns.

SEC original ↗Chemed Corp — 10-K Annual report10-KFeb 27, 2026

Risks & headwinds

 Reiterate Guidance for 2025  Management reiterates its previously issued guidance of $22.00 to $22.30 per share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

 Because forward looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Chemed’s control.

SEC original ↗Chemed Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Legal Proceedings 23 Item 4.

SEC original ↗Chemed Corp — 10-K Annual report10-KFeb 27, 2026

Such statements involve risks and uncertainties that could cause actual results of operations to differ materially from these forward-looking statements.

SEC original ↗Chemed Corp — 10-K Annual report10-KFeb 27, 2026

If a VITAS hospice were found to be out of compliance and actions were taken against a VITAS hospice, they could materially adversely affect the hospice s ability to continue to operate, to provide certain services and to participate in the Medicare and Medicaid programs, which could materially adversely affect VITAS.

SEC original ↗Chemed Corp — 10-K Annual report10-KFeb 27, 2026

In addition, competitors may seek administratively or judicially to challenge such an approval or proposed approval by the state agency.

SEC original ↗Chemed Corp — 10-K Annual report10-KFeb 27, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

31 documents

Earnings releases

14 documents

Presentations

0 documents

No presentations for Chemed Corp are held in this edition of the library.

Transcripts

0 documents

No transcripts for Chemed Corp are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.